Last reviewed · How we verify

NCT06069791

Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1

Recruiting now Phase 1 Last updated 29 January 2026
What this trial tests

Phase 1 trial testing Bupivacaine Injection in Post-Traumatic Headache in 12 participants. Currently enrolling.

Timeline
26 January 2024
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorYale University
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposeother
Enrollment12
Start date26 January 2024
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

18 and older, any sex, with Post-Traumatic Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bupivacaine Injection

Trials testing the same drug.

Other recruiting trials for Post-Traumatic Headache

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06069791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing